Dr. David H. Fine is the founder and Chairman of GeNO. Dr. Fine served as President of GeNO from inception until December 2011, and then as Chief Executive Officer until August 2013. He has 40 years of experience leading innovation development and transitioning high technology chemistry-based instruments from research through production and into commercialization. In 2000, Dr. Fine co-founded CyTerra Corporation, a company focused on advanced technology for the detection of buried land mines. Dr. Fine served as Chief Executive Officer of CyTerra from 2000 until 2006. Prior to co-founding CyTerra, Dr. Fine worked for 28 years at Thermo Electron Corporation. During his tenure at Thermo Electron, Dr. Fine published extensively on the formation of carcinogenic N-nitrosamines, the detection of NO and NO using chemiluminescence, the detection of explosives for forensic and airport security by converting them to NO, and then measuring the NO, and many other detection systems using the NO moiety. Dr. Fine held various leadership positions at Thermo Electron, including Vice President of Thermedics Inc. and Senior Vice President of Thermedics Detection Inc., both of which were publicly-traded subsidiaries of Thermo Electron. His last assignment at Thermo Electron was as President of Thermo Electron’s R&D Center Inc. From 1969 to 1972. While on the academic staff of the Chemical Engineering Department at MIT, Dr. Fine worked on the formation and mitigation of NO formed in combustion systems and NO related air pollution chemistry. Dr. Fine has published over 100 technical papers in peer reviewed technical literature, including Nature and Science. He is also the inventor on 83 issued U.S. patents, including over 60 patents on NO/NO based chemistry and instrumentation.
Brent Furse, CEO and President
Brent Furse has served as a Director and our Chief Executive Officer and President since June 2016. Prior to coming to GeNO, Mr. Furse was a key member of the The Medicines Company leadership team where he joined in 2000 pre-IPO and served as a section 16 Officer. Held various leadership positions including Executive Vice President and Chief Commercial Officer, Vice President and General Manager Interventional Medicine, Vice President Surgery and Perioperative Care, and Vice President of Sales and Marketing. He was responsible for the launch and success of their flagship product Angiomax, and countless successful partnerships and operational excellence. In addition to his success at The Medicines Company, Brent has held leadership positions with Centers for Disease Control, Bristol-Myers Squibb, and Schering Plough Corporation, and serves on the board of Anthera Pharmaceuticals, The Special Olympics and Salus Tele-health.
Scott Johnson, MD
Scott Johnson is Chief Medical Advisor at The Medicines Company. He is responsible for the medical affairs function of the business development team that identifies business opportunities based on changes in the medical and healthcare environment. During the past 4 years, he has been responsible for the licensing or acquisition of the potential blockbuster products PCSsc (an RNAi synthesis inhibitor for hypercholesterolemia) and ABP-700 (a novel intravenous anesthetic for induction and maintenance of anesthesia and procedural sedation). Scott is also responsible for evaluating the company’s long-range global strategy. Dr. Johnson was a co-founder of MDCO and was a Director from September 1996 until July 2009 when he joined management on a full-time basis. Previously, Scott was a founding General Partner at JSB Partners, L.P., an investment bank with a focus on mergers and acquisitions, private financings and corporate alliances within the healthcare sector. From September 1991 to July 1999, Scott served as a founder and managing director of MPM Capital, LLC, a venture capital firm. Dr. Johnson holds a B.S. in chemistry (Phi Beta Kappa) and an M.D. (Alpha Omega Alpha) from the University of Alabama. His academic career included faculty positions at Harvard Medical School, the University of Colorado Medical School, and the University of South Alabama. He is Board Certified in Internal Medicine, Pulmonary and Critical Care Medicine and Sleep Disorders Medicine.
Mr. Theo Melas-Kyriazi is an Independent Director at GeNO LLC, Chief Financial Officer at Levitronix Technologies LLC, Independent Director at Valeant Pharmaceuticals International, Inc., Operating Executive at SFW Capital Partners LLC, and Chief Financial Officer at Pharos LLC. Mr. Theo Melas-Kyriazi has served as a Manager of GeNO since September 2013. Mr. Melas-Kyriazi has served as Chief Financial Officer of Levitronix Technologies LLC since 2011 and previously served as the CFO of its affiliate, Levitronix, LLC since 2006. He was the Chief Financial Officer of Thermo Electron (now Thermo Fisher Scientific, NYSE: TMO) from 1999-2004, and served in other management roles at TMO from 1966-1999. Mr. Melas-Kyriazi also served as director of Valeant Pharmaceuticals International, Inc (NYSE: VRX) until June 2016, and as a director of Moderna Theraputics LLC. He is on the Board of Directors at Moderna Therapeutics, Inc., GeNO LLC, Valeant Pharmaceuticals International, Inc., and Elemé Medical, Inc. Mr. Melas-Kyriazi was previously employed as Independent Director by Helicos Biosciences Corp., Chief Financial & Accounting Officer by Thermo Fibergen, Inc., President & Chief Executive Officer by ThermoSpectra Corp, and Chief Financial Officer by Thermo Electron Corp. He also served on the board at Cyberkinetics Neurotechnology Systems, Inc. and GlenRose Instruments, Inc. Mr. Melas-Kyriazi received an AB in Economics from Harvard College, and an MBA from the Harvard Business School.
Vinzenz Ploerer is President and CEO of Brace Pharma Capital. He is a Life Science executive with 30 plus years of extensive leadership experience in operations, acquisitions, and business development. Prior to launching Brace, Vinzenz worked at EMS S/A as Senior Vice President of Strategy and Operations. Mr. Ploerer has held various leadership positions at Novartis/Sandoz including Country Head of Brazil, Argentina, and Head of BDL Sandoz, building the company through acquisitions. Mr. Ploerer currently sits on several corporate boards including GeNO, Therabron, Tyrogenex, and Navitor.
Todd Brady currently serves as the Director of Finance and Investments at Brace Pharma Capital. Mr. Brady also serves as a director for Brace portfolio companies, GeNO LLC, and Tyrogenex, as well as a board observer for Avidity Nanomedicines and Miragen Therapeutics. Mr. Brady has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Mr. Brady has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).
Daniel E Salazar, PhD
Dr Salazar is an accomplished pharmaceutical research and development executive with significant accomplishments across all phases of development and different therapeutic areas. His core areas of expertise are in translational science, clinical development, clinical pharmacology, pharmacokinetics, biopharmaceutics, pharmacometrics molecular pharmacology, pharmacogenomics, outsourcing, regulatory strategy, biomarkers, companion diagnostics and digital health. He has more than 25 years of experience in drug discovery, development, regulatory submissions and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs including Abilify®, Benicar HCT®, Azor®, Tribenzor®, Welchol®, Effient® and Sayvasa®. He is currently, Chief Scientific Officer and a member of the Board of Director of EMS Pharma, the leading pharmaceutical company in Brazil and Latin America. Dr Salazar is also Vice President Clinical and Regulatory, Brace Pharma Capital, the venture capital company of EMS Pharma located in Rockville, MD. Dr Salazar is the Acting Chief Technical Officer and a member of the Board of Managers for GeNO LLC. He also is Acting Sr Vice President of Development and Director for Tyrogenex, Inc. Dr Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo. He has directed over 100 clinical studies investigating dosage form bioequivalence, drug absorption, first administration to man, proof of concept, pharmacokinetics, pharmacodynamics, disease state interactions and drug-drug interactions. Dr Salazar is the co-author of 5 book chapters and 80 articles in peer reviewed journals.